Skip to content

PHARMEDIC

Active Private limited companyfounded 2018active for 7 yearsRue du Fays 1, 5336 AssesseKBO/BCE: BE 0715.682.133 #6 company by total assets in Assesse, Manufacturing sector
PHARMEDIC
Follow ReportCompare

Overview

Lifetime

7 annual accounts with figures on one time axis
peak €223,924 (2025)
€223,924▲ 37.9%
peak €54,336 (2025)
€54,336▲ 189%
peak €129,921 (2025)
€129,921▲ 71.9%
€1.2m▼ 4.8%
peak 2.1 FTE (2020)
-not published
Board4 names since 2018
2 directorsDamienne HALLEUX and 1 other
Documentsfilings and deeds
26-08-202626 days late
2025micro format
Gross margin from €162,418 to €223,924Result from €18,777 to €54,336Equity from €75,585 to €129,921Cash from €100,486 to €57,121

Key points

from the 2025 annual accounts

Equity

€129,921 ▲ 71.9%
€75,6002024€130,0002025

Equity rose in 2025 from €75,585 to €129,921.

Turnover

≈ €560,000 estimated

The micro format states no turnover.

Debts

€1.2m 90% of the balance sheet
Financial debts 70%Suppliers 4%Taxes and wages 1%Other 25%

Of this, €351,768 falls due within a year.

Filings

7 annual accounts 7 late
AprilJune31 JulyOctober202020222024

The 2023 accounts came latest: 61 days after the end of the period.

Position in the sector

10.1%

Lower solvency than 84% of companies in fabricated metal products. Sector median 44.2% · 2,343 companies.

Checked score

64
Healthy
Financially stronger than 42% of micro companies in fabricated metal products (NACE 25)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
1.4% Low
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: 0.5% across 3,709 companies (NACE 25, micro).

About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 2.9% 01-2025: 2.9%● unchanged vs 12-2024 02-2025: 3.0%▲ +0.1 percentage points vs 01-2025 03-2025: 2.5%▼ -0.5 percentage points vs 02-2025 04-2025: 2.8%▲ +0.3 percentage points vs 03-2025 05-2025: 3.3%▲ +0.5 percentage points vs 04-2025 06-2025: 3.6%▲ +0.3 percentage points vs 05-2025 07-2025: 3.8%▲ +0.2 percentage points vs 06-2025 08-2025: 2.6%▼ -1.2 percentage points vs 07-2025 09-2025: 2.8%▲ +0.2 percentage points vs 08-2025 10-2025: 4.1%▲ +1.3 percentage points vs 09-2025highest value 11-2025: 1.7%▼ -2.4 percentage points vs 10-2025 12-2025: 1.7%● unchanged vs 11-2025 01-2026: 1.7%● unchanged vs 12-2025 02-2026: 1.7%● unchanged vs 01-2026 03-2026: 1.8%▲ +0.1 percentage points vs 02-2026 04-2026: 1.8%● unchanged vs 03-2026 05-2026: 1.9%▲ +0.1 percentage points vs 04-2026 06-2026: 2.1%▲ +0.2 percentage points vs 05-2026 07-2026: 2.2%▲ +0.1 percentage points vs 06-2026 08-2026: 2.7%▲ +0.5 percentage points vs 07-2026 09-2026: 1.4%▼ -1.3 percentage points vs 08-2026lowest value 10-2026: 1.4%● unchanged vs 09-2026lowest value 11-2026: 1.4%● unchanged vs 10-2026lowest value

Financial strength
Average

35+4equity 10.1% of total assets
45-4short-term debt 27.4% · cash 4.4%
62+11return on assets 4.2%

Score breakdown

raises risk
Last filed accounts filed 26 days late; 2 of the last 3 accounts late
Equity €129,921 (10.1% of total assets)
Sector: Manufacture of fabricated metal products, except machinery and equipment (NACE 25)
lowers risk
Size: total assets €1.3m
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 25, micro). It does better than 14% of them on solvency, 34% on liquidity, 29% on profitability and 90% on growth.

The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 3,274 companies had the same profile as PHARMEDIC has now. Each dot stands for 9 companies, two years later.

94.7%
were still trading
2.5%
stopped another way
2.5%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

That fits the bankruptcy probability of PHARMEDIC itself: 1.4% within 12 months.

Test of the method

The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,274 companies, not a prediction for PHARMEDIC. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €8,000 on 30-day terms is acceptable

Liquidity is tight, with a current ratio of 1.01 (0.94 in 2024), below the usual 1.5. Short-term debt is 27.4% and cash 4.4% of total assets. 89.9% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises risk
raises risk · Last filed accounts filed 26 days late; 2 of the last 3 accounts late
NBB · filings
lowers risk · Size: total assets €1.3m
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · Equity €129,921 (10.1% of total assets)
NBB · annual accounts
raises risk · Sector: Manufacture of fabricated metal products, except machinery and equipment (NACE 25)
KBO
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 16% of 2343 sector peers (2025).
NBB · sector comparison
Position among 2343 sector peers
Solvency
better than 16%
← weakest strongest →
raises risk · 2025 accounts filed 26 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-08-2026, 26 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 7 filings
Deviation from the deadline
2025
26 days late
2024
60 days late
2023
61 days late
2022
31 days late
2021
31 days late
2020
30 days late
2019
31 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 39 days after the deadline. In the sector (NACE 25), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

DH
Damienne HALLEUX
Director
JF
Jean-François JADIN
Director
  • JADIN Jean-François Henri Marie-Rose 50 sharesdeed of 13-12-2018
  • HALLEUX Damienne Anne Emmanuelle Ghislaine 50 sharesdeed of 13-12-2018
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0715682133
Company renamed from STEEL & MORE to PHARMEDIC Registered office moved from Hemptinne to Courrière · New registered office: Rue du Fays, numéro 1, 5336 Courrière · Previous registered office: Rue des Cortys 12, 5380 Hemptinne (Fernelmont) · General meeting of 28-06-2023 · Gazette deed
New establishment in Assesse Pharma Courrière, Rue du Fays 1
Changes of role: Damienne HALLEUX (director) and Jean-François JADIN (director) “La ferronnerie; La construction métallique; L’ébénisterie; La fabrication et la pose de menuiseries…” (deed in French) · Director discharge: Damienne HALLEUX · Director discharge: Jean-François JADIN · General meeting of 16-02-2023 · Gazette deed
All 17 events

Comparable companies

same main activity, similar in size and age
Company
PHARMEDIC Assesse €1.3m €223,924 10.1% -
Smederij Van de Velde Geert Berlare €1.0m €249,157 30.5% -
WAUTEAM Fleurus €1.6m €310,698 4.6% -
GEURTS CORP. Bassenge €1.0m €172,667 18.1% -
SMEDERIJ DE BRUYN Aalst €0.9m €262,142 12.0% -
MY STEEL Malmedy €0.8m €281,516 19.2% 3.3
VDH Constructie Stekene €1.2m €452,953 35.9% -

These companies have the same main activity as PHARMEDIC: forging of metal (NACE 25401). They are comparable in size and age: total assets between €756,000 and €1.6m, founded between 2015 and 2021.

Official details

Source: KBO
Status
Active since 11-12-2018Normal situation
Activity
Forging of metalNACE 25401and 1 other
Establishment units
2.282.785.0335081 La Bruyère, since 11-12-2018
2.339.827.8625380 Fernelmont, since 01-12-2022and 1 other
Financial year end
31 December
Peppol
Reachable since 18-01-2026
Company details

Annual accounts 2025

€223,924▲ 37.9%
€54,336▲ 189%
€129,921▲ 71.9%
€1.3m▼ 0.3%
Employeeson 31-12-2025
1=
Filing
Filed on 26-08-2026
Financials

Insights on PHARMEDIC

PHARMEDIC files the micro format. That format states no turnover. The gross margin rose from €118,903 in 2019 to €223,924 in 2025.

The balance sheet grew most from 2021 to 2023 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

micro format, filed on 26-08-2026, 26 days late
€223,924
▲ 37.9%
€109,203
▲ 91.1%
€54,336
▲ 189%
€5,100
▲ €26,373
10.1%
▲ 4.2 percentage points
1.01
▲ 0.08

Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.

Turnover ≈ €560,000. Estimated: probably between €370,000 and €870,000.

In the rankings #6 company by total assets in Assesse, Manufacturing sector

Balance sheet

balance sheet total €1.3m on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

10.1%

Higher than 16% of 2,343 companies in 2025.

1.01

Higher than 27% of 2,309 companies in 2025.

4.2%

Higher than 43% of 2,323 companies in 2025.

PHARMEDIC Middle half of the sector 80% of the sector Micro accounts in fabricated metal products (NACE 25)

Net result: top quarter · Equity: middle half · Balance sheet total: top quarter · Working capital: middle half

Staff

€37,788

Staff costs divided by the average number of full-time equivalents.

people who joined people who left

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202420232022202120202019
Balance sheet: assets
20/58 1.3m1.3m1.3m183,165151,059146,933207,721
21/28 927,829969,253976,04423,79346,73573,56194,964
21 143,500162,661182,4191,4963,3545,6998,044
22/27 784,329806,591793,62522,29743,38167,86286,920
22 709,016702,345721,213----
23 34,13745,0406,91011,75423,54538,66553,788
24 41,17659,20765,50210,54319,83529,19733,132
29/58 356,868319,702318,961159,371104,32573,373112,757
3 210,245163,384145,98368,40035,000-30,000
30/36 210,245163,384109,183----
37 --36,80068,40035,000-30,000
40/41 87,24254,16750,53984,50959,90757,31066,923
40 62,27935,64646,01384,21359,61132,02229,432
41 24,96318,5214,52629629625,28837,491
54/58 57,121100,486117,4863,3068,50215,03514,674
490/1 2,2611,6664,9533,1569161,0281,160
Balance sheet: equity and liabilities
10/49 1.3m1.3m1.3m183,165151,059146,933207,721
10/15 129,92175,58556,80855,21444,92940,48832,971
10/11 18,60018,60018,60018,60018,60018,60018,600
100 ------18,600
13 81,25626,9208,2208,2208,2208,220720
130/1 720720720720720720-
130 ------720
1311 720720720720720720-
133 80,53626,2007,5007,5007,5007,500-
14 30,06530,06529,98828,39418,10913,66813,651
17/49 1.2m1.2m1.2m127,950106,131106,445174,750
17 803,008872,395907,2321,84823,86345,59367,042
170/4 803,008872,395907,2321,84823,86345,59367,042
42/48 351,768340,975330,964126,10282,26860,703107,708
42 70,42974,43658,93622,01521,73021,44921,171
43 6,7326,757----6,692
430/8 6,7326,757----6,692
44 47,53620,55750,57865,21032,86033,23734,233
440/4 47,53620,55750,57865,21032,86033,23734,233
45 9,1094,7617,5227,01722,9175,7405,621
450/3 3,6822,006629-11,109750-
454/9 5,4272,7546,8947,01711,8094,9905,621
47/48 217,962234,465213,92731,8614,76127739,990
492/3 -----149-
Income statement
9900 223,924162,418179,884115,994104,324100,489118,903
62 34,00929,16373,42281,55071,37863,61877,931
630 78,97874,20885,76722,94126,82626,45022,720
640/8 1,7331,9047681643096531,205
9901 109,20357,14419,92811,3395,8119,76917,047
75/76B 81-581-11112
75 81-581-11112
65/66B 41,78136,49718,9151,0531,3721,6122,678
65 41,78136,49718,9151,0531,3721,6122,678
9903 67,50320,6471,59410,2864,4418,26814,371
67/77 13,1671,870---750-
9904 54,33618,7771,59410,2864,4417,51814,371
9905 54,33618,7771,59410,2864,4417,51814,371
Appropriation of the result
9906 84,40148,76529,98828,39418,10921,16814,371
14P 30,06529,98828,39418,10913,668--
691/2 54,33618,700---7,500720
6920 ------720
6921 54,33618,700---7,500-
Social balance sheet
9087 0.90.523.12.92.12
Hours worked1013 1,1449552,6513,3523,1522,6833,528
Document PDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 13 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 26-08-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

2025 annual accounts filed 26 days after the deadline. Filed on 26 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00447245.

Financial year Type Filed Reference Document
31-12-2025 micro format 26-08-2026 2026-00447245 PDF
31-12-2024 micro format 29-09-2025 2025-00523051 PDF
31-12-2023 micro format 30-09-2024 2024-00489734 PDF
31-12-2022 micro format 31-08-2023 2023-00427229 PDF
31-12-2021 micro format 31-08-2022 2022-20409484 PDF
31-12-2020 micro format 30-08-2021 2021-57700307 PDF
31-12-2019 micro format 31-08-2020 2020-47800527 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202420232022202120202019
188,181131,352105,69434,28032,63736,21839,767
133,31592,98587,36033,22731,26733,96737,091
37,55467,4171.0m005,046117,685
-43,365-17,001114,180-5,196-6,534361-
5,100-21,273-12,00333,26922,05712,6695,049
10.1%5.9%4.4%30.1%29.7%27.6%15.9%
1.010.940.961.261.271.211.05
0.420.460.520.720.841.210.77
8.8916.0521.802.322.362.635.30
41.8%24.8%2.8%18.6%9.9%18.6%43.6%
4.2%1.5%0.1%5.6%2.9%5.1%6.9%
4.503.605.5932.5623.79--

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date11133
full-time--133
part-time11---
in full-time equivalents0.80.5133
0.70.523.12.9
On a permanent contract11133
Joined-10--
Left-12--

Source: social balance sheet in the 2021 to 2025 annual accounts

Securities and guarantees

on own assets and for others
Item20252024202320222021
Mortgages, amount registered€27,500€27,500€27,500--
€665,000€665,000€665,000--
Carrying value of the mortgaged assets€610,928€629,828€648,728--
€170,000€170,000€170,000€120,000€120,000

Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€37,554€67,417€846,403--
Intangible fixed assets--€191,614--
€78,978€74,208€85,767€22,941€26,826

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on PHARMEDIC

The operating result for 2025 is 91% higher than in 2024 and the highest since 2019. It is the fourth rise in a row, after the fall in 2021.

Debt's share of the balance-sheet total falls from 94.1% to 89.9%. Equity is higher and debt is lower.

Board & ownership

Board

2 directors, no change since 2023
Damienne HALLEUX
Director
appointed by deed of 08-03-2023 term without a fixed end
earlier manager, until 08-03-2023
Jean-François JADIN
Director
appointed by deed of 08-03-2023 term without a fixed end
earlier manager, until 08-03-2023
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“Article 12. Pouvoirs de l’organe d’administration S’il n’y a qu’un seul administrateur, la totalité des pouvoirs d’administration lui est…”
deed of 08-03-2023

Office holders in the KBO →

Mandates through the years

4 names, the dashed line is today
Damienne HALLEUX
Director (not named in the articles)
Jean-François JADIN
Director (not named in the articles)
HALLEUX Damienne Anne Emmanuelle Ghislaine
Manager (not named in the articles)
JADIN Jean-François Henri Marie-Rose
Manager (not named in the articles)
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
  • Damienne HALLEUX
    • Director (not named in the articles), appointed by deed of 08-03-2023, still in office
    • Manager, until 08-03-2023
  • Jean-François JADIN
    • Director (not named in the articles), appointed by deed of 08-03-2023, still in office
    • Manager, until 08-03-2023
  • HALLEUX Damienne Anne Emmanuelle Ghislaine
    • Manager (not named in the articles), appointed by deed of 13-12-2018, last mentioned in 2018
  • JADIN Jean-François Henri Marie-Rose
    • Manager (not named in the articles), appointed by deed of 13-12-2018, last mentioned in 2018

See the board, name and registered office on a given date →

Control

Founders
JADIN Jean-François Henri Marie-Rose, HALLEUX Damienne Anne Emmanuelle Ghislaine
This company
PHARMEDIC
Equity €129,921
Profit €54,336 in 2025

Capital

Contribution
€18,600
Shares
100
Contribution per share
€186
Equity per share
€1,299 in 2025
Source
2025 annual accounts

Articles of association

deed of 08-03-2023 (in French)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
“Moitié cédant moitié acquéreurs au prorata si plusieurs, commun accord sinon président du tribunal de l'entreprise statuant comme en référé…”
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Monday of June

Shareholders

At incorporation deed of 13-12-2018 ↗

Capital transactions

Capital over time
  1. 08-03-2023 Converted to unavailable equity · €19,320
  2. 13-12-2018 Incorporation · €18,600 · 100 shares

Network & group

No group

PHARMEDIC has no parent and no holdings in its annual accounts. PHARMEDIC shares no director with another company.

Timeline

Timeline

17 events since 2018

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed NBBmicro format · 26 days late
Registered in the Peppol Directory Reachable for e-invoices through 0208:0715682133
2025
Highest result from 2019 to 2025 net €54,336 ▲189% The operating result of €109,203 and the net result of €54,336 are both a record.
Equity above €100,000 equity €129,921 ▲71.9% With a profit in every financial year since 2019, equity grows to €129,921.
Annual accounts 2024 filed PDFmicro format · 60 days late
2024
Annual accounts 2023 filed PDFmicro format · 61 days late
2023
Weakest financial year net €1,594 ▼84.5% The net result drops to €1,594, the lowest from 2019 to 2025. It recovers the following year.
Annual accounts 2022 filed PDFmicro format · 31 days late
Company renamed from STEEL & MORE to PHARMEDICRegistered office moved from Hemptinne to Courrière · New registered office: Rue du Fays, numéro 1, 5336 Courrière · Previous registered office: Rue des Cortys 12, 5380 Hemptinne (Fernelmont) · General meeting of 28-06-20236 points ▸
  • General meeting, 28-06-2023
  • Name change, PHARMEDIC
  • Director reappointment, Damienne HALLEUX
  • Director reappointment, Jean-François JADIN
  • Registered-office move, Rue du Fays, numéro 1, 5336 Courrière
  • Power of attorney, David REMY

Open the deed in the Belgian Official Gazette

New establishment in Assesse Pharma Courrière, Rue du Fays 1
Changes of role: Damienne HALLEUX (director) and Jean-François JADIN (director)“La ferronnerie; La construction métallique; L’ébénisterie; La fabrication et la pose de menuiseries…” (deed in French) · Director discharge: Damienne HALLEUX · Director discharge: Jean-François JADIN · General meeting of 16-02-20239 points ▸
  • General meeting, 16-02-2023
  • Purpose change, “La ferronnerie; La construction métallique; L’ébénisterie; La fabrication et la pose de menuiseries métalliques; La fabrication et la pose de clôtures; La…” (deed in French)
  • Director resignation, Damienne HALLEUX (manager)
  • Director resignation, Jean-François JADIN (manager)
  • Director appointment, Damienne HALLEUX (director (not named in the articles))
  • Director appointment, Jean-François JADIN (director (not named in the articles))
  • Director discharge, Damienne HALLEUX
  • Director discharge, Jean-François JADIN
  • Registered office clause, Rue des Cortys 12, 5380 Hemptinne (Fernelmont)
  • The deed holds 6 more points.

Open the deed in the Belgian Official Gazette

2022
New establishment in Fernelmont STEEL & MORE, Rue des Cortys, Hempt. 12
Annual accounts 2021 filed PDFmicro format · 31 days late
2021
Annual accounts 2020 filed PDFmicro format · 30 days late
2020
Annual accounts 2019 filed PDFmicro format · 31 days late
2018
IncorporationFounding capital of €18,600, 100 shares · Founders: JADIN Jean-François Henri Marie-Rose and HALLEUX Damienne Anne Emmanuelle Ghislaine · Appointments: JADIN Jean-François Henri Marie-Rose (manager) and HALLEUX Damienne Anne Emmanuelle Ghislaine (manager) · published on 13-12-20185 points ▸

Open the deed in the Belgian Official Gazette

First establishment STEEL & MORE, Chaussée d'Eghezée, Meux 46, La Bruyère

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 11 December 2018, PHARMEDIC was incorporated by two natural persons, with a starting capital of €18,600.12 Since 2023 the company has been called PHARMEDIC.3 In 2023 the registered office moved to Courrière.3 Today the board has 2 members.4 Total assets went from €207,721 in 2019 to €1.3m in 2025 and headcount from 2 to 0.9 full-time equivalents.5

  1. 1KBO register
  2. 2Belgian Official Gazette, 13-12-2018
  3. 3Belgian Official Gazette, 19-07-2023
  4. 4Belgian Official Gazette, 08-03-2023
  5. 5National Bank, annual accounts 2019 and 2025

Company details

Identity

Enterprise number
0715.682.133
VAT number
BE 0715.682.133
Peppol ID
0208:0715682133
Other Peppol ID
9925:BE0715682133
Legal form
Private limited company
Status
Active, normal situation
Founded
11-12-2018
Financial year
ends on 31 December
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Monday of June
deed of 08-03-2023 (in French)
Peppol
Reachable since 18-01-2026Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
PHARMEDIC in French
Trade name
STEEL & MORE / PHARMACOURRIERE in French
Former name
STEEL & MORE until the deed of 19-07-2023
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 08-03-2023 (in French)

Activities

NACEBEL 2025
VAT activities
25401 Forging of metal main activity
Social security (RSZ) activities
47730 Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
VAT activities
25501 Manufacture of fabricated metal products, except machinery and equipment main activity
Social security (RSZ) activities
47730 Retail trade main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“La ferronnerie; La construction métallique; L’ébénisterie; La fabrication et la pose de menuiseries métalliques; La fabrication et la pose…”
29 activities
  1. La ferronnerie
  2. La construction métallique
  3. L’ébénisterie
  4. La fabrication et la pose de menuiseries métalliques
  5. La fabrication et la pose de clôtures
  6. La vitrerie
  7. La menuiserie
  8. La construction de tous types de bâtiments
  9. La conception,la fabrication,l’achat et la vente,la réparation de tout matériel agricole ou horticole
  10. L’achat et la vente en gros et au détail de matériel se rapportant aux activités cidessus
  11. L'exploitation de pharmacies
  12. L’activité de pharmacien dans le sens le plus large du terme
  13. Les autres activités de soutien aux entreprises non classées ailleurs
  14. La fabrication,la commercialisation et le commerce,de gros ou détail,de tous produits médicamenteux,de préparation magistrale allopathiques ou homéopathiques,de produits chimiques,pharmaceutiques,parapharmaceutiques,hygiéniques,diététiques,médicaux,dentaires,homéopathiques,d’herboristerie,de bandagisterie,d’acoustique,de droguerie,d’optique,de parfumerie et de tous produits dérivés
  15. La fabrication,la commercialisation et le commerce,de gros ou de détail,de tous matériels de laboratoire
  16. L’achat et la vente au détail de produits et d’accessoires pharmaceutiques ou parapharmaceutiques,l’achat,la vente ou location de matériel(par exemple,aérosol,béquilles…)et de tous articles se rattachant même indirectement à la pharmacie
  17. La consultance,la formation,le recyclage,l’enseignement,l’organisation de conférences ou séminaires,dans les domaines scientifiques et pharmaceutiques
  18. L’acquisition ou la création de tous brevets,licences,marques de fabrique ou de commerce
  19. La participation à la création et au développement d'entreprises industrielles,commerciales,financières ou immobilières destinées ou liées au secteur pharmaceutique au sens large,dans la mesure de la conformité avec toutes dispositions légales et/ou réglementaires
  20. La gestion d’un patrimoine mobilier et immobilier,tant en Belgique,qu'à l'étranger,pour compte propre,ou pour compte de tiers,ou en participation avec des tiers
  21. Toutes opérations d’achat,de vente,de transformation,d’aménagement,de conclusion de baux commerciaux et/ou civils,de sous-location,d’échange et de vente de tous immeubles à l’exclusion de l’entreprise d’achat d’immeubles en vue de la revente
  22. Contracter ou consentir tout prêt généralement quelconque
  23. Tout ce qui est utile ou nécessaire et toutes opérations commerciales,industrielles,mobilières,immobilières ou financières se rattachant directement ou indirectement à son objet dont achat,vente,location de biens appartenant à la société
  24. S’intéresser par apport,fusion,souscription,intervention financière ou autre mode dans sociétés à objet similaire ou connexe ou favorisant extension
  25. Recours à association,partenariat ou sous-traitance d’entreprises titulaires des accès,agréations ou enregistrements requis
  26. Acquérir,aliéner,prendre/donner en location immeuble ou fonds,acquérir/céder brevets,licences,marques,s’intéresser à sociétés d’objet similaire ou utile à extension ou résiliation partielle
  27. Placements en valeurs mobilières et sûretés pour compte de tiers
  28. Fonctions d’administrateur ou liquidateur dans d’autres sociétés
  29. Caution et sûretés personnelles ou réelles pour toute personne liée ou non
deed of 08-03-2023 (in French)

Registered office and establishments

3 establishments
Establishment Since Unit number
STEEL & MORE Chaussée d'Eghezée, Meux 46, 5081 La Bruyère 11-12-2018 2.282.785.033
STEEL & MORE Rue des Cortys, Hempt. 12, 5380 Fernelmont 47730 Retail sale of pharmaceutical products 01-12-2022 2.339.827.862
Pharma Courrière registered office Rue du Fays 1, 5336 Assesse 21100 Manufacture of basic pharmaceutical products and pharmaceutical preparations 01-07-2023 2.346.335.572
1 former office
  • 5380 Hemptinne(Fernelmont) until the deed of 19-07-2023

Buildings and parcels at the addresses

Ground area
1.3 ha
Buildings
555 m²
Volume, LiDAR
4,186 m³
Tallest building
12.1 m
Buildings to scale, each on its own parcel
216 m², 12.1 m 193 m², 7.3 m 146 m², 8.6 m 216 m², 12.1 m 193 m², 7.3 m 146 m², 8.6 m

Location

registered office establishment All 3 establishment units on the map

Parcels

Cadastral parcelArea Buildings Height / floors
92088B0140/00T0009,474 m² 1 · 216 m² 12.1 m · 3
92063B0076/00H0002,369 m² 1 · 146 m² 8.6 m · 2
92028A0513/00H0051,240 m² 1 · 193 m² 7.3 m · 2

Contact

E-mail info@steelandmore.be
Phone +32 474 86 02 77
Phone +32 81 47 91 24 establishment in Assesse

We would like to set cookies. That happens only with your consent. What we measure